influenza

[NPJ Biofilms and Microbiomes] Investigators found that human nasal commensal Staphylococcus epidermidis promoted protease–protease inhibitor balance in favor of the host and prevented influenza A virus replication in the nasal mucosa and lungs.

[Cocrystal Pharma, Inc.] Cocrystal Pharma, Inc. reported preliminary results of a Phase I study with CC-42344, a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza A, demonstrating a favorable safety and pharmacokinetic profile.

[SyneuRx™ International] SyneuRx™ International announced it has completed enrollment for its Phase II clinical trial evaluating the efficacy and safety of SNB01 ('Pentarlandir’), a novel COVID-19 oral antiviral candidate.

[Human Vaccines & Immunotherapeutics] Scientists investigated the effects of CYNK-001, human placental hematopoietic stem cell derived NK cells that exhibited strong cytolytic activity against a range of malignant cells and expressed high levels of activating receptors, against influenza A virus infections.

[NPJ Vaccines] Researchers generated a virus-like particle (VLP) vaccine bearing the hemagglutinin of H1N1 A/California/07/09 that was unable to bind to its α(2,6)-linked sialic acid receptor and compared its immunogenicity and efficacy to a wild-type H1-VLP in mice.

[NPJ Vaccines] Researchers generated a virus-like particle (VLP) vaccine bearing the hemagglutinin of H1N1 A/California/07/09 that was unable to bind to its α(2,6)-linked sialic acid receptor and compared its immunogenicity and efficacy to a wild-type H1-VLP in mice.